NIFK

Summary

NIFK (nucleolar protein interacting with the FHA domain of MKI67, HGNC:17838) is a protein-coding gene on chromosome 2q14.3, encoding MKI67 FHA domain-interacting nucleolar phosphoprotein (Q9BYG3). It is a common-essential gene (DepMap: required in 99.8% of cancer cell lines).

This gene encodes a protein that interacts with the forkhead-associated domain of the Ki-67 antigen. The encoded protein may bind RNA and may play a role in mitosis and cell cycle progression. Multiple pseudogenes exist on chromosomes 5, 10, 12, 15, and 19.

Source: NCBI Gene 84365 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 35 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 99.8% of screened cell lines (common-essential)
• MANE Select transcript: NM_032390

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17838
Approved symbol	NIFK
Name	nucleolar protein interacting with the FHA domain of MKI67
Location	2q14.3
Locus type	gene with protein product
Status	Approved
Aliases	Nop15, Nopp34, hNIFK
Ensembl gene	ENSG00000155438
Ensembl biotype	protein_coding
OMIM	611970
Entrez	84365

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 3 retained_intron

ENST00000285814, ENST00000423105, ENST00000447132, ENST00000451734, ENST00000477693, ENST00000481978, ENST00000498570, ENST00000911491, ENST00000911492, ENST00000911493, ENST00000911494

RefSeq mRNA: 1 — MANE Select: NM_032390 NM_032390

CCDS: CCDS2135

Canonical transcript exons

ENST00000285814 — 7 exons

Exon	Start	End
ENSE00001159639	121726945	121727912
ENSE00001632880	121736746	121736875
ENSE00001732800	121730893	121731104
ENSE00003516872	121732096	121732204
ENSE00003576680	121735613	121735750
ENSE00003589924	121728477	121728536
ENSE00003596668	121728288	121728356

Expression profiles

Bgee: expression breadth ubiquitous, 261 present calls, max score 98.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 44.7172 / max 886.3918, expressed in 1812 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
30469	29.9291	1803
30470	9.6675	1731
30471	5.1206	1642

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	98.74	gold quality
ventricular zone	UBERON:0003053	96.12	gold quality
tendon	UBERON:0000043	95.78	gold quality
embryo	UBERON:0000922	95.52	gold quality
ganglionic eminence	UBERON:0004023	95.52	gold quality
cartilage tissue	UBERON:0002418	95.50	gold quality
tibialis anterior	UBERON:0001385	95.32	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.03	gold quality
adrenal tissue	UBERON:0018303	95.01	gold quality
body of pancreas	UBERON:0001150	94.33	gold quality
lymph node	UBERON:0000029	94.06	gold quality
colonic mucosa	UBERON:0000317	93.75	gold quality
pancreas	UBERON:0001264	93.73	gold quality
endometrium	UBERON:0001295	93.60	gold quality
vermiform appendix	UBERON:0001154	93.59	gold quality
islet of Langerhans	UBERON:0000006	93.21	gold quality
pericardium	UBERON:0002407	93.17	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.15	gold quality
upper arm skin	UBERON:0004263	93.09	gold quality
left ovary	UBERON:0002119	93.03	gold quality
cortical plate	UBERON:0005343	93.00	gold quality
ovary	UBERON:0000992	92.91	gold quality
smooth muscle tissue	UBERON:0001135	92.91	gold quality
esophagus mucosa	UBERON:0002469	92.81	gold quality
leukocyte	CL:0000738	92.72	gold quality
monocyte	CL:0000576	92.69	gold quality
epithelial cell of pancreas	CL:0000083	92.67	gold quality
peritoneum	UBERON:0002358	92.58	gold quality
omental fat pad	UBERON:0010414	92.57	gold quality
rectum	UBERON:0001052	92.54	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	8.60
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting NIFK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-4424	98.91	70.33	1145
HSA-MIR-5000-3P	98.79	65.63	1251
HSA-MIR-876-3P	98.76	68.23	945
HSA-MIR-2276-3P	98.76	67.75	1384
HSA-MIR-5008-3P	98.73	67.50	1433
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-323A-5P	98.59	65.13	651
HSA-MIR-603	98.58	68.28	1603
HSA-MIR-4252	98.45	66.37	987
HSA-MIR-302F	98.44	69.02	1776
HSA-MIR-6780A-3P	98.42	67.49	1518
HSA-MIR-6837-3P	98.42	66.71	1149
HSA-MIR-6864-5P	98.38	66.59	1079

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.8% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 5)

• nmr analysis of the solution structure of the FHA domain of human Ki67 and mapping of the binding surface for NIFK binding (PMID:14659764)
• Potential encounter complexes of the Ki67FHA receptor and hNIFK peptide are misregistered states of the beta-sheet. (PMID:21539773)
• The RNA recognition motif of NIFK is required for rRNA maturation during cell cycle progression. (PMID:25826659)
• NIFK is required for lung cancer progression via the RUNX1-dependent CK1alpha repression, which activates TCF4/beta-catenin signaling in metastasis and the Ki-67-dependent regulation in cell proliferation. (PMID:26984280)
• NIFK as a potential prognostic biomarker in colorectal cancer correlating with immune infiltrates. (PMID:37800782)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	nifk	ENSDARG00000040666
mus_musculus	Nifk	ENSMUSG00000026377
rattus_norvegicus	Nifk	ENSRNOG00000025701

Protein

Protein identifiers

MKI67 FHA domain-interacting nucleolar phosphoprotein — Q9BYG3 (reviewed: Q9BYG3)

Alternative names: Nucleolar phosphoprotein Nopp34, Nucleolar protein interacting with the FHA domain of pKI-67

All UniProt accessions (4): Q9BYG3, C9J6C5, C9J808, H7BZL0

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Binds to the FHA domain of MKI67; this interaction is enhanced in mitosis.

Subcellular location. Nucleus. Nucleolus. Chromosome.

Post-translational modifications. Sequentially phosphorylated on Thr-238, Thr-234 and Ser-230. Thr-234 is phosphorylated only when Thr-238 is phosphorylated. Likewise, phosphorylation at Ser-230 requires that Thr-234 and Thr-238 are phosphorylated. Phosphorylation enhances MKI67 binding.

RefSeq proteins (1): NP_115766* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR021043	NIFK_FHA_Ki67-binding	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily

Pfam: PF00076, PF12196

UniProt features (36 total): modified residue 13, cross-link 6, mutagenesis site 5, region of interest 3, helix 2, compositionally biased region 2, initiator methionine 1, chain 1, domain 1, sequence variant 1, strand 1

Structure

Experimental structures (PDB)

25 structures.

PDB	Method	Resolution (Å)
8FKV	ELECTRON MICROSCOPY	2.47
8FLE	ELECTRON MICROSCOPY	2.48
8FKW	ELECTRON MICROSCOPY	2.5
8FL3	ELECTRON MICROSCOPY	2.53
8FL7	ELECTRON MICROSCOPY	2.55
8FLB	ELECTRON MICROSCOPY	2.55
8FLD	ELECTRON MICROSCOPY	2.58
8FKX	ELECTRON MICROSCOPY	2.59
8FL6	ELECTRON MICROSCOPY	2.62
8FLA	ELECTRON MICROSCOPY	2.63
8FKY	ELECTRON MICROSCOPY	2.67
8FL2	ELECTRON MICROSCOPY	2.67
8FKQ	ELECTRON MICROSCOPY	2.76
8FKT	ELECTRON MICROSCOPY	2.81
8FKU	ELECTRON MICROSCOPY	2.82
8FKP	ELECTRON MICROSCOPY	2.85
8FKS	ELECTRON MICROSCOPY	2.88
8FKR	ELECTRON MICROSCOPY	2.89
8INF	ELECTRON MICROSCOPY	3
8FKZ	ELECTRON MICROSCOPY	3.04
8INE	ELECTRON MICROSCOPY	3.2
8IPY	ELECTRON MICROSCOPY	3.2
8IR3	ELECTRON MICROSCOPY	3.5
8IPX	ELECTRON MICROSCOPY	4.3
2AFF	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BYG3-F1	73.56	0.35

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (19): 145, 218, 223, 230, 234, 238, 244, 245, 247, 279, 284, 38, 139, 179, 192, 271, 271, 2, 114

Mutagenesis-validated functional residues (5):

Position	Phenotype
230	loss of phosphorylation site.
234	loss of phosphorylation site. abrogates interaction with mki67.
235	reduces phosphorylation at t-234.
238	loss of phosphorylation site. abrogates interaction with mki67.
239	reduces phosphorylation at t-234 and t-238.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 121 (showing top): GSE45365_NK_CELL_VS_BCELL_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_RRNA_TRANSCRIPTION, WEI_MYCN_TARGETS_WITH_E_BOX, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, MODULE_207, chr2q14, GOCC_NUCLEOLUS, SCGGAAGY_ELK1_02, GOCC_NUCLEAR_CHROMOSOME, GOCC_CONDENSED_NUCLEAR_CHROMOSOME

GO Biological Process (3): rRNA transcription (GO:0009303), rRNA metabolic process (GO:0016072), protein-containing complex assembly (GO:0065003)

GO Molecular Function (3): RNA binding (GO:0003723), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (6): condensed nuclear chromosome (GO:0000794), nucleoplasm (GO:0005654), chromosome (GO:0005694), nucleolus (GO:0005730), cytoplasm (GO:0005737), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
nuclear lumen	2
cellular anatomical structure	2
intracellular membraneless organelle	2
DNA-templated transcription	1
rRNA metabolic process	1
RNA metabolic process	1
cellular component assembly	1
protein-containing complex organization	1
nucleic acid binding	1
nuclear chromosome	1
condensed chromosome	1
nucleus	1
intracellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

3092 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NIFK	MKI67	P46013	856
NIFK	RSL1D1	O76021	744
NIFK	DDX18	Q9NVP1	741
NIFK	NIP7	Q9Y221	739
NIFK	WDR12	Q9GZL7	680
NIFK	MAK16	Q9BXY0	671
NIFK	EBNA1BP2	Q99848	670
NIFK	GNL3	Q9BVP2	659
NIFK	PA2G4	Q9UQ80	624
NIFK	GTPBP4	Q9BZE4	609
NIFK	MRTO4	Q9UKD2	585
NIFK	BOP1	Q14137	561
NIFK	NOC2L	Q9Y3T9	559
NIFK	POLR1B	Q9H9Y6	555
NIFK	BRIX1	Q8TDN6	540

IntAct

150 interactions, top by confidence:

A	B	Type	Score
MKI67	NIFK	psi-mi:“MI:0407”(direct interaction)	0.750
MKI67	NIFK	psi-mi:“MI:0915”(physical association)	0.750
N	HNRNPR	psi-mi:“MI:0914”(association)	0.730
CSNK2B	RPS6KA5	psi-mi:“MI:0914”(association)	0.660
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
CSNK2A1	SURF6	psi-mi:“MI:0914”(association)	0.590
NIFK	TNIP1	psi-mi:“MI:0915”(physical association)	0.560
TNIP1	NIFK	psi-mi:“MI:0915”(physical association)	0.560
RPL28	MAGEB2	psi-mi:“MI:0914”(association)	0.560
ZCRB1	DKC1	psi-mi:“MI:0914”(association)	0.530
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530
NIFK	RSL1D1	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
NIFK	PPP1CA	psi-mi:“MI:0407”(direct interaction)	0.440
LTK	PIK3R2	psi-mi:“MI:0914”(association)	0.420
NEFH	NIFK	psi-mi:“MI:0915”(physical association)	0.400
PHF3	NIFK	psi-mi:“MI:0915”(physical association)	0.400
OR5H8	NIFK	psi-mi:“MI:0915”(physical association)	0.400
CCDC68	NIFK	psi-mi:“MI:0915”(physical association)	0.400
Mki67	PPP1CA	psi-mi:“MI:0915”(physical association)	0.400
NIFK		psi-mi:“MI:0915”(physical association)	0.370
ZDHHC17	NIFK	psi-mi:“MI:0915”(physical association)	0.370
JUN		psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
NP	HNRNPAB	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350

BioGRID (676): NIFK (Two-hybrid), NIFK (Two-hybrid), NIFK (Affinity Capture-MS), NIFK (Affinity Capture-MS), NIFK (Affinity Capture-MS), NIFK (Affinity Capture-MS), NIFK (Affinity Capture-MS), NIFK (Affinity Capture-MS), NIFK (Affinity Capture-MS), LARP7 (Affinity Capture-MS), RPL26L1 (Affinity Capture-MS), RPF1 (Affinity Capture-MS), YBX2 (Affinity Capture-MS), RBM28 (Affinity Capture-MS), YTHDC2 (Affinity Capture-MS)

ESM2 similar proteins: A3LVD5, A7EAY2, O13620, O13741, O74362, O74400, O74978, P37838, P42696, P53743, P53883, P53927, Q01491, Q06106, Q07623, Q08208, Q09100, Q1E7Y4, Q2GZQ4, Q3SZM1, Q4PC17, Q4WCH5, Q5AHI7, Q5AJS6, Q5BDC8, Q5M9F1, Q5RJM0, Q6BTS9, Q6C007, Q6C2Q7, Q6CEW9, Q6CFT1, Q6CKV6, Q6CQR6, Q6FUS6, Q6FWS2, Q6FXP4, Q6GL69, Q757I6, Q75A83

Diamond homologs: A0A0A0LLY1, A0A0D1C8Z4, A0A0R4IEW8, A7EWN6, B0BN49, B5DF91, C0HFE5, D3Z4I3, M0R7T6, O09032, O22703, O23212, O35698, O43040, O74978, O94290, P19684, P25299, P26368, P26369, P26378, P33240, P48810, P49311, P70372, P90727, P90978, P97343, P98179, Q00916, Q03250, Q03878, Q05966, Q08473, Q08935, Q08E07, Q10B98, Q12926, Q13595, Q14576

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CDK1	“up-regulates activity”	NIFK	phosphorylation
GSK3A	“up-regulates activity”	NIFK	phosphorylation
GSK3B	“up-regulates activity”	NIFK	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 160 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Eukaryotic Translation Initiation	6	17.8×	2e-05
Cap-dependent Translation Initiation	6	17.8×	2e-05
SARS-CoV-1 modulates host translation machinery	6	17.8×	2e-05
Eukaryotic Translation Elongation	6	16.1×	4e-05
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	6	15.7×	4e-05
Peptide chain elongation	12	14.6×	3e-09
Viral mRNA Translation	12	14.6×	3e-09
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	12	14.5×	3e-09

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription by RNA polymerase III	5	33.2×	3e-05
negative regulation of viral genome replication	7	18.6×	1e-05
cytoplasmic translation	13	17.1×	5e-10
ribosomal large subunit biogenesis	5	15.7×	1e-03
ribosomal small subunit biogenesis	9	14.5×	2e-06
rRNA processing	14	14.1×	5e-10
regulation of alternative mRNA splicing, via spliceosome	6	10.4×	2e-03
translation	14	10.2×	3e-08

Disease & clinical

Clinical variants and AI predictions

ClinVar

35 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

837 predictions. Top by Δscore:

Variant	Effect	Δscore
2:121728358:T:C	acceptor_gain	1.0000
2:121730889:TTACC:T	donor_loss	1.0000
2:121730890:TAC:T	donor_loss	1.0000
2:121730891:A:AC	donor_gain	1.0000
2:121730892:C:CC	donor_gain	1.0000
2:121730892:C:CG	donor_loss	1.0000
2:121730914:AATT:A	donor_gain	1.0000
2:121730917:T:TA	donor_gain	1.0000
2:121730927:G:C	donor_gain	1.0000
2:121730937:T:TA	donor_gain	1.0000
2:121730955:T:A	donor_gain	1.0000
2:121731100:ATGAC:A	acceptor_gain	1.0000
2:121731101:TGAC:T	acceptor_gain	1.0000
2:121731102:GAC:G	acceptor_gain	1.0000
2:121731103:AC:A	acceptor_gain	1.0000
2:121731104:CC:C	acceptor_gain	1.0000
2:121731104:CCTA:C	acceptor_loss	1.0000
2:121731105:C:CA	acceptor_loss	1.0000
2:121731105:C:CC	acceptor_gain	1.0000
2:121731109:T:C	acceptor_gain	1.0000
2:121731112:C:CT	acceptor_gain	1.0000
2:121731113:A:T	acceptor_gain	1.0000
2:121732090:ACTT:A	donor_loss	1.0000
2:121732091:CTTAC:C	donor_loss	1.0000
2:121732093:TAC:T	donor_gain	1.0000
2:121732094:A:AC	donor_gain	1.0000
2:121732094:A:AG	donor_loss	1.0000
2:121732094:ACA:A	donor_gain	1.0000
2:121732094:ACACT:A	donor_gain	1.0000
2:121732095:C:CT	donor_gain	1.0000

AlphaMissense

1916 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:121735652:A:C	F68L	0.995
2:121735652:A:T	F68L	0.995
2:121735654:A:G	F68L	0.995
2:121732169:A:C	F93L	0.993
2:121732169:A:T	F93L	0.993
2:121732171:A:G	F93L	0.993
2:121732178:A:C	F90L	0.993
2:121732178:A:T	F90L	0.993
2:121732180:A:G	F90L	0.993
2:121732182:G:T	A89E	0.989
2:121735622:T:A	R78S	0.989
2:121735622:T:G	R78S	0.989
2:121732152:G:T	A99D	0.987
2:121735716:A:T	V47D	0.986
2:121731064:A:C	F131L	0.985
2:121731064:A:T	F131L	0.985
2:121731066:A:G	F131L	0.985
2:121732096:A:G	C118R	0.985
2:121735650:C:A	G69V	0.985
2:121731103:A:C	C118W	0.983
2:121732141:C:G	A103P	0.982
2:121732153:C:G	A99P	0.979
2:121732176:A:T	V91E	0.979
2:121732170:A:G	F93S	0.978
2:121732143:A:T	V102D	0.977
2:121735710:A:T	V49E	0.976
2:121732183:C:G	A89P	0.975
2:121732190:T:A	K86N	0.975
2:121732190:T:G	K86N	0.975
2:121730930:A:G	L176S	0.974

dbSNP variants (sampled 300 via entrez): RS1000500782 (2:121727465 T>C), RS1000526848 (2:121737477 C>A), RS1000813779 (2:121737760 C>G,T), RS1001079870 (2:121726528 T>TG), RS1001153569 (2:121737135 G>C), RS1001204696 (2:121734947 A>T), RS1001236362 (2:121726927 C>T), RS1001458732 (2:121729507 C>T), RS1001803362 (2:121729298 G>A), RS1002182621 (2:121733615 A>G), RS1002235095 (2:121733752 A>G), RS1002345647 (2:121728079 T>G), RS1002432429 (2:121731319 C>G), RS1002483796 (2:121738692 G>C), RS1002860281 (2:121735314 A>G)

Disease associations

OMIM: gene MIM:611970 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009391_2054	Metabolite levels	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010345	cholesteryl ester 18:2 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523443 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, affects cotreatment, increases expression	5
sodium arsenite	increases abundance, increases expression, affects binding, increases reaction, decreases expression (+1 more)	4
trichostatin A	affects cotreatment, increases expression	3
Valproic Acid	affects expression, increases expression, increases methylation	3
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment, decreases expression	2
Plant Extracts	affects cotreatment, increases expression, decreases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects cotreatment, decreases expression, increases expression	2
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	increases expression	1
arsenite	affects binding, increases reaction	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
4-phenylbutyric acid	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
2-amino-14,16-dimethyloctadecan-3-ol	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
bisphenol S	affects expression	1
LDN 193189	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4341436	Binding	Binding affinity to MKI67 in human A549 cells lysates grown on SILAC media at 10 uM incubated for 1 hr by LC-MS/MS analysis relative to untreated control	Profiling withanolide A for therapeutic targets in neurodegenerative diseases. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.